Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug;34(8):2276-2278.
doi: 10.1038/s41375-020-0907-9. Epub 2020 Jun 17.

Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

Andreas Neubauer  1 , Thomas Wiesmann  2 , Claus F Vogelmeier  3 , Elisabeth Mack  4 , Chrysanthi Skevaki  5 , Christine Gaik  2 , Christian Keller  6 , Jens Figiel  7 , Kristina Sohlbach  4 , Caroline Rolfes  2   8 , Harald Renz  5 , Hinnerk Wulf  2 , Andreas Burchert  4
Affiliations
Comment

Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

Andreas Neubauer et al. Leukemia. 2020 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1. Ruxolitinib clears lung infiltration in SARS-CoV-2 induced ARDS.
a Chest CT scans of the patient before transfer to the ICU reveals diffuse bilateral ground glass opacities, consolidations, and motion artifacts due to tachypnea. b After 11 days of treatment with ruxolitinib, markedly decreased ground glass opacities and motion artifacts, less pronounced regression of consolidations, and atelectasis.
Fig. 2
Fig. 2. Ruxolitinib improves functional and inflammatory parameters in SARS-CoV-2 induced ARDS.
Functional lung parameters (a) and laboratory parameters (b; ferritin and IL6) during treatment with ruxolitinib in a case of COVID-19 related ARDS.
See this image and copyright information in PMC

Comment on

References

    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl J Med. 2020;382:727–33. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. Lippi G, Mattiuzzi C, Sanchis-Gomar F, Henry BM. Clinical and demographic characteristics of patients dying from COVID-19 in Italy versus China. J Med Virol. 2020. - PMC - PubMed
    1. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020. - PMC - PubMed
    1. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620–9. doi: 10.1172/JCI137244. - DOI - PMC - PubMed
    1. La Rosée F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, et al. The Janus kinase 1/2 inhibitor Ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020. - PMC - PubMed